INBX
Inhibrx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$121.17
−0.89%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.7x
Market Cap
$1.78B
MomentumView details →
1D Return
−0.89%
YTD Return
+56.77%
RSI (14)
69.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.7x
Market Cap
$1.78B
RSI (14)
69.3
MomentumView details →
1D Return
−0.89%
YTD Return
+56.77%
SummaryUpdated Jun 1, 2026
Inhibrx Biosciences, Inc. (NASDAQ:INBX) is a clinical-stage biopharmaceutical company founded in 2024 and based in La Jolla, California. The company went public on June 4, 2024, representing a spinoff from its parent company Inhibrx, Inc. Inhibrx Biosciences focuses on developing innovative biologic therapeutics for patients with life-threatening conditions, particularly in oncology. The company operates as a pure-play biotechnology firm dedicated to advancing two primary drug candidates through clinical trials.
Similar companies
Latest newsMore news →
Inhibrx entered into an amended loan agreement with Oxford Finance, expanding the total facility to $500.0 million and receiving an initial $100.0 million tranche.51d agoInhibrx announced that the U.S. FDA accepted for filing its Biologics License Application for ozekibart to treat unresectable or metastatic conventional chondrosarcoma.82d ago